Bristol Myers' Opdivo-Yervoy Combo Meets Main Goal in Liver Cancer Trial Bristol Myers' Opdivo-Yervoy Combo Meets Main Goal in Liver Cancer Trial
Bristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a late-stage study evaluating it as an initial treatment for a type of liver...Reuters Health Information (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 20, 2024 Category: Internal Medicine Tags: Hematology-Oncology Source Type: news
Bristol Myers Liver Cancer Treatment Meets Main Goal Of Late-stage Study Bristol Myers Liver Cancer Treatment Meets Main Goal Of Late-stage Study
Bristol Myers Squibb said on Wednesday a combination of its drugs, Opdivo and Yervoy, met the main goal of a late-stage study evaluating it as an initial treatment for a...Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 20, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
FDA Fast Tracks UV1 Vaccine Combo for Mesothelioma
The U.S. Food and Drug Administration granted fast-track designation to a new therapeutic cancer vaccine. The approval is for UV1 in combination with the immunotherapy drugs Opdivo (nivolumab) and Yervoy (ipilimumab) to manage malignant pleural mesothelioma that can’t be managed with surgery.
Therapeutic cancer vaccines, unlike preventive vaccines, treat existing cancers. Fast Track expedites the development of drug reviews for severe conditions. This way, the FDA can bring essential new drugs to patients earlier. With this designation, UV1 drug-maker Ultimovacs ASA will interact more frequently with the FDA dur...
Source: Asbestos and Mesothelioma News - February 21, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC
First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Does Adding Ipilimumab to Nivolumab Improve Cancer Outcomes? Does Adding Ipilimumab to Nivolumab Improve Cancer Outcomes?
Nivolumab alone may offer equivalent clinical outcomes and lower toxicity than nivolumab plus ipilimumab in many advanced cancers other than melanoma, a new meta-analysis suggests.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 18, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
Trial Shows Keytruda With Chemotherapy Superior to Chemo Alone
Results of a new phase 3 clinical trial published in the Journal of Clinical Oncology indicate that a chemoimmunotherapy regimen combining chemotherapy with immunotherapy drugs improves patient survival more than chemotherapy alone for pleural mesothelioma.
Study researchers used pembrolizumab (Keytruda) alongside platinum and pemetrexed chemotherapy. Christina S. Baik, MD, MPH, reviewed the phase 3 trial results during the American Society of Clinical Oncology’s 2023 Best of ASCO Seattle annual meeting.
The overall response rate for patients receiving Keytruda with chemotherapy was 63% compared to 40% for th...
Source: Asbestos and Mesothelioma News - September 13, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Chemotherapy/Chemo drugs Immunotherapy Mesothelioma Treatment Source Type: news
Six-Year Follow-Up Data on CheckMate 227 Survival and Quality of Life Benefits Unveiled for Patients with Metastatic NSCLC and Nivolumab + Ipilimumab Treatment
SINGAPORE, Sept. 10, 2023 /PRNewswire-PRWeb/ -- The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 10, 2023 Category: Pharmaceuticals Tags: TRI SVY Source Type: news
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
WEDNESDAY, Aug. 23, 2023 -- For patients with metastatic melanoma who receive frontline anti-programmed death protein 1 (PD-1) or therapy against programmed cell death 1 ligand 1 and whose tumors progressed with cytotoxic T-lymphocyte protein 4... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 23, 2023 Category: Pharmaceuticals Source Type: news
Immunotherapy drug combo helps extend lives of people with metastatic melanoma
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to widely used immunotherapy drugs called PD-1 inhibitors.In clinical trials, the investigators found that the combination therapy could extend the amount of time patients live without their cancer worsening, known as progression-free survival, and that it helps overcome their resistance to prior immunotherapies — which would allow more people to benefit from the treatment.The study evaluated the use of the imm...
Source: UCLA Newsroom: Health Sciences - August 18, 2023 Category: Universities & Medical Training Source Type: news
Cabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer
THURSDAY, May 11, 2023 -- Cabozantinib plus nivolumab and ipilimumab yields significantly longer progression-free survival than treatment with cabozantinib plus nivolumab alone among patients with previously untreated, advanced renal-cell carcinoma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2023 Category: Pharmaceuticals Source Type: news
Possible Role for Ipilimumab in Metastatic Bladder Cancer, Study Suggests
(MedPage Today) -- A tailored immunotherapy regimen using nivolumab (Opdivo) induction and "boosts" with nivolumab and high-dose ipilimumab (Yervoy) as second-line treatment for metastatic urothelial cancer was associated with higher response rates... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 2, 2023 Category: Hematology Source Type: news
Study Shows Opdivo, Yervoy Effective After Mesothelioma Surgery
This study tested the safety and efficacy of two drugs following mesothelioma surgery after cancer recurrence. The combination of immunotherapy drugs nivolumab and ipilimumab, known by the brand names Opdivo and Yervoy, was recently approved for mesothelioma.
The new treatment led to a 6-month survival of 87% in pleural mesothelioma patients. The 12-month survival rate was 74.2%.
“Nivolumab with ipilimumab has promising efficacy in treating recurrent MPM [malignant pleural mesothelioma] in the postoperative setting,” the authors wrote.
The authors also noted a higher rate of adverse events than in prior s...
Source: Asbestos and Mesothelioma News - January 30, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Pleural Source Type: news
Mesothelioma Surgery With Immunotherapy Proves Effective in Study
An immunotherapy combination given before aggressive surgery has shown impressive effectiveness in extending survival for pleural mesothelioma patients in a recent phase II clinical trial at Baylor College of Medicine.
The combination of immune checkpoint inhibitors durvalumab and tremelimumab showed an ability to effectively alter the intratumoral immune system and make surgery more effective.
This randomized clinical trial compared the use of durvalumab alone – already shown to be effective in other cancers – to both the two-drug combination and to using no immunotherapy before mesothelioma surgery.
Clinica...
Source: Asbestos and Mesothelioma News - December 19, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Pleural Source Type: news
Tumor - Infiltrating Lymphocytes Up PFS in Advanced Melanoma
Significantly longer progression - free survival seen with infusion of tumor - infiltrating lymphocytes versus ipilimumab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 8, 2022 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pathology, Journal, Source Type: news
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Abstract Background Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1–2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes…#nationalcenterforcancerimmunetherap #hospitalpharmacyandclinicalchemistry #dutchcancersociety #nejmorg #qualityassuranceandqualitycontrol #marjoleindelfos #anjafvanderwal #divisionofmolecularoncologyandimmun #loespronk #haanen (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2022 Category: Consumer Health News Source Type: news
